Accordingly, IL-6 is regarded as a key mediator of RA pathogenesis in clinical settings, and IL-6 receptor inhibitors, such tocilizumab and sarilumab, have shown notable effectiveness in lowering inflammation and averting structural damage [76]. The gene discussed is IL6; the disease is rheumatoid arthritis.